Leonard C. Weir
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Atrial Fibrillation Management and Outcomes, Protease and Inhibitor Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Chemical Synthesis and Analysis
Most-Cited Works
- → Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain(2003)237 cited
- → Sulfonimidamide Analogs of Oncolytic Sulfonylureas,1(1997)97 cited
- → 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa(2000)49 cited
- → N2-Aroylanthranilamide Inhibitors of Human Factor Xa(2000)48 cited
- → Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity(2000)46 cited
- → D-Phe-Pro-p-Amidinobenzylamine: A potent and highly selective thrombin inhibitor(1996)41 cited
- → Serine protease selectivity of the thrombin inhibitor D-Phe-Pro-Agmatine and its homologs(1995)36 cited
- → The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding element(1999)26 cited
- → Anthranilamide inhibitors of factor Xa(2007)18 cited
- → N-substituted glycines as replacements for proline in tripeptide aldehyde thrombin inhibitors(1995)10 cited